The useful question is not "do peptides work?" It's "which ones have real human data, and which ones are still a promising animal story?" That single distinction sorts almost everything below.
Peptides are short chains of amino acids that act as signaling molecules in the body. They differ from proteins mainly in length. Some occur naturally, others are synthetic or semi-synthetic. Their clinical legitimacy varies widely. A few have known receptors and well-characterized mechanisms. Many do not, and that gap is the central safety distinction.
This is a summary of a Huberman Lab conversation with Dr. Abud Bakri, MD, a board-certified internal medicine physician. It is shared here as education, not as medical advice or a recommendation to use anything described below.
Well studied, with known receptors and large-scale human trials. Now commonly stacked with other peptides and hormones. The best-characterized group on the list.
Stimulate the body's own growth hormone rather than replacing it. Concerns center on raised IGF-1 and long-term cancer risk, especially with a cancer history. Higher IGF-1 also tracks with shorter lifespan across species.
A synthetic peptide derived from a protein in gastric juice. Strong healing and anti-inflammatory effects in animals, but nearly all of it from one Croatian group. No robust human trials yet. Not FDA-approved, status evolving.
Used topically, sometimes systemically. Modulates collagen and has antioxidant properties. Generally lower risk because of topical use. Popular in aesthetics and anti-aging.
A tetrapeptide originally developed in Russia. Associated with telomere lengthening, better REM sleep, and possible neuroprotection. Intriguing animal data, limited human evidence.
A tripeptide linked to melatonin-adjacent pathways. Touted for sleep and neuroprotection. Human data is limited.
Used for tanning and sexual function respectively. Both carry meaningful safety concerns and regulatory issues.
01The one question that sorts safety
Dr. Bakri's core heuristic is simple: does the peptide have a known receptor? Compounds like GLP-1 agonists, with well-characterized receptors and established pharmacology, are far safer than peptides like BPC-157 whose mechanisms are still unclear.
Questions worth asking first
- Is there human trial data, or only animal data?
- Who funded and conducted the research?
- Is it compounded or pharmaceutical-grade? Purity and sterility of compounded peptides is a real concern.
- Does it promote angiogenesis? This matters for anyone with cancer risk.
- What is your baseline: hormone levels, metabolic panel, personal and family cancer history?
The most important differentiator is not hype. It's quality of evidence.
02The "celebrity / CEO protocol"
A growing trend combines a GLP-1, a growth hormone secretagogue, and testosterone replacement therapy. The visible results are rapid fat loss and muscle gain. Whether it is healthy long-term is simply unknown. Dr. Bakri does not endorse this stack, and he stresses the gap between short-term aesthetics and long-term safety data.
03Regulation and sourcing
Many peptides are sold as research chemicals and are not FDA-approved. Compounding pharmacies vary widely in quality. The FDA's evolving Category 1 vs. Category 2 classification directly affects which peptides can be legally prescribed. As the rules tighten, access to BPC-157 and others may change substantially.
04The bottom line
Peptides are a scientifically promising but largely under-studied class of compounds. A few, like GLP-1s and Tesamorelin, have strong human data. Most others have compelling but preliminary animal data only. Anyone considering peptides should work with a knowledgeable physician, get baseline labs, understand the purity and sourcing risks, and approach with calibrated skepticism rather than hype.